LAKESHORE BIOPHARMA CO LTD (LSB) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:LSB • KYG9845F2080

0.627 USD
-0.16 (-20.68%)
At close: Sep 19, 2025
0.5399 USD
-0.09 (-13.89%)
After Hours: 9/19/2025, 8:26:53 PM

LSB Key Statistics, Chart & Performance

Key Statistics
Market Cap25.84M
Revenue(TTM)614.96M
Net Income(TTM)-99.98M
Shares41.21M
Float5.08M
52 Week High5.7
52 Week Low0.57
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.73
PEN/A
Fwd PE4.39
Earnings (Next)12-15
IPO2021-07-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
LSB short term performance overview.The bars show the price performance of LSB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

LSB long term performance overview.The bars show the price performance of LSB in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15

The current stock price of LSB is 0.627 USD. In the past month the price decreased by -25%. In the past year, price decreased by -18.57%.

LAKESHORE BIOPHARMA CO LTD / LSB Daily stock chart

LSB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LSB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LSB. LSB may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LSB Financial Highlights

Over the last trailing twelve months LSB reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 87.13% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.31%
ROE -20.01%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%70.82%
Sales Q2Q%79.55%
EPS 1Y (TTM)87.13%
Revenue 1Y (TTM)7.24%

LSB Forecast & Estimates

5 analysts have analysed LSB and the average price target is 31.62 USD. This implies a price increase of 4943.06% is expected in the next year compared to the current price of 0.627.

For the next year, analysts expect an EPS growth of 105.67% and a revenue growth 75.61% for LSB


Analysts
Analysts80
Price Target31.62 (4943.06%)
EPS Next Y105.67%
Revenue Next Year75.61%

LSB Ownership

Ownership
Inst Owners0.66%
Ins Owners12.67%
Short Float %N/A
Short RatioN/A

LSB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.39394.886B
AMGN AMGEN INC17.06206.949B
GILD GILEAD SCIENCES INC17.1189.204B
VRTX VERTEX PHARMACEUTICALS INC23.44121.258B
REGN REGENERON PHARMACEUTICALS16.9182.557B
ALNY ALNYLAM PHARMACEUTICALS INC48.9943.353B
INSM INSMED INC N/A31.961B
BIIB BIOGEN INC13.2229.513B
NTRA NATERA INC N/A28.022B
INCY INCYTE CORP13.5421.279B

About LSB

Company Profile

LSB logo image LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Company Info

LAKESHORE BIOPHARMA CO LTD

Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District

Beijing BEIJING CN

Employees: 573

LSB Company Website

LSB Investor Relations

Phone: 17327133678

LAKESHORE BIOPHARMA CO LTD / LSB FAQ

Can you describe the business of LAKESHORE BIOPHARMA CO LTD?

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.


Can you provide the latest stock price for LAKESHORE BIOPHARMA CO LTD?

The current stock price of LSB is 0.627 USD. The price decreased by -20.68% in the last trading session.


What is the dividend status of LAKESHORE BIOPHARMA CO LTD?

LSB does not pay a dividend.


What is the ChartMill rating of LAKESHORE BIOPHARMA CO LTD stock?

LSB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of LAKESHORE BIOPHARMA CO LTD (LSB)?

LAKESHORE BIOPHARMA CO LTD (LSB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).


Is LAKESHORE BIOPHARMA CO LTD (LSB) expected to grow?

The Revenue of LAKESHORE BIOPHARMA CO LTD (LSB) is expected to grow by 75.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the ownership structure of LAKESHORE BIOPHARMA CO LTD (LSB)?

You can find the ownership structure of LAKESHORE BIOPHARMA CO LTD (LSB) on the Ownership tab.